Rhee, Moo-Yong; Kim, Cheol Ho; Ahn, Youngkeun; Shin, Joon-Han; Han, Seung Hwan; Kang, Hyun-Jae; Hong, Soon Jun; Kim, Hae-Young
Drug design, development and therapy
2020NA ; 14 ( 21 ) :5005-5017.
PMID : 33235439
저자 상세정보
Rhee, Moo-Yong - Cardiovascular Center, Dongguk University Ilsan Hospital, Goyang, Republic of Korea.
Kim, Cheol Ho - Department of Internal Medicine, Seoul National University Bundang Hospital,
Ahn, Youngkeun - Division of Cardiology, Department of Internal Medicine, Chonnam National University
Shin, Joon-Han - Department of Cardiology, Ajou University Medical Center, Suwon, Republic of Korea.
Han, Seung Hwan - Division of Cardiology, Department of Internal Medicine, Gachon University Gil
Kang, Hyun-Jae - Department of Internal Medicine, Seoul National University Cardiovascular Center,
Hong, Soon Jun - Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital,
Kim, Hae-Young - Department of Health Policy and Management, College of Health Science & Department
ABSTRACT
PURPOSE: We evaluated the efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with hypertension and hyperlipidemia. PATIENTS AND
METHODS: Eligible patients, after more than 4 weeks of therapeutic lifestyle change, were randomly assigned to three groups: 5 mg nebivolol plus 20 mg rosuvastatin (NEBI/RSV), 20 mg rosuvastatin (RSV), or 5 mg nebivolol (NEBI). Treatments lasted 8 weeks.
RESULTS: Efficacy was analyzed using data from 276 patients. Sitting systolic and diastolic blood pressures differed between the NEBI/RSV and RSV groups (LSmean difference = -5.89 and -5.99 mmHg; 95% confidence interval [CI] = -9.88 to -1.90 mmHg and -8.13 to -3.84 mmHg, respectively). Reductions in the two pressures did not differ between the NEB/RSV and NEB groups. The percent reduction in low-density lipoprotein (LDL) cholesterol differed between the NEBI/RSV and NEBI groups (LSmean difference = -47.76%, 95% CI = -52.69 to -42.84%) but not between the NEBI/RSV and RSV groups. The blood pressure (BP) control rate was higher in the NEBI/RSV group than in the RVS group (51.09% vs 29.67%, p = 0.003). The LDL cholesterol goal achievement rate was higher in the NEBI/RSV group than in the NEBI group (85.87% vs 11.83%, p < 0.001). The incidence of adverse drug reactions in the NEBI/RSV, RSV, and NEBI groups was 8.51%, 7.45%, and 8.60%, respectively (p = 0.950). CONCLUSION: Nebivolol plus rosuvastatin treatment is effective in reducing BP and LDL cholesterol levels and is safe in patients with hypertension and hypercholesterolemia without the loss of BP or the LDL cholesterol-lowering effect of each drug. TRIAL REGISTRATION: CRIS registration number KCT0002148. CI - ??2020 Rhee et al.
keyword
hypercholesterolemia; hypertension; nebivolol; rosuvastatin
링크